Literature DB >> 15885122

The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells.

Laëtitia Maçon-Lemaître1, Frédéric Triebel.   

Abstract

Accumulating evidence indicates that the CD4 homologue lymphocyte activation gene-3 (LAG-3) plays a down-regulatory role on T-cell responses. However, the role of LAG-3/major histocompatibility complex (MHC) class II interactions on primary human T-cell responses, as well as the mechanism by which down-regulation occurs, are not clear. Here, we show that LAG-3 colocalized with CD3, CD4 or CD8 in areas of cholesterol-rich raft aggregation during this primary response, as well as in the clustered raft region formed between T cells and antibody-coated beads. Addition of a blocking LAG-3-specific monoclonal antibody to both CD4 and CD8 primary resting T cells activated under conditions of antigen-presenting cell-driven stimulation and low antigen concentrations augments CD69 activation antigen expression, T-cell expansion and T helper 1 (Th1, but not Th2) cytokine production. Blocking LAG-3/MHC class II interactions leads to an increase in the number of cells entering division at these low concentrations of antigen and to more rounds of divisions with an accumulation of cells in the S-phase of the cell cycle. These results indicate that LAG-3 signalling inhibits early events in primary activation of human CD4 and CD8 T cells and further support a role for LAG-3 signalling in regulating the expansion of activated effector or memory T cells, either directly or indirectly through Treg suppressor activity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15885122      PMCID: PMC1782137          DOI: 10.1111/j.1365-2567.2005.02145.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  27 in total

1.  CTLA-4 regulates cell cycle progression during a primary immune response.

Authors:  Rebecca J Greenwald; Mariette A Oosterwegel; Diane van der Woude; Anup Kubal; Didier A Mandelbrot; Vassiliki A Boussiotis; Arlene H Sharpe
Journal:  Eur J Immunol       Date:  2002-02       Impact factor: 5.532

2.  The MHC class II ligand lymphocyte activation gene-3 is co-distributed with CD8 and CD3-TCR molecules after their engagement by mAb or peptide-MHC class I complexes.

Authors:  S Hannier; F Triebel
Journal:  Int Immunol       Date:  1999-11       Impact factor: 4.823

3.  LAP, a lymphocyte activation gene-3 (LAG-3)-associated protein that binds to a repeated EP motif in the intracellular region of LAG-3, may participate in the down-regulation of the CD3/TCR activation pathway.

Authors:  N Iouzalen; S Andreae; S Hannier; F Triebel
Journal:  Eur J Immunol       Date:  2001-10       Impact factor: 5.532

4.  Antigen-induced translocation of PKC-theta to membrane rafts is required for T cell activation.

Authors:  K Bi; Y Tanaka; N Coudronniere; K Sugie; S Hong; M J van Stipdonk; A Altman
Journal:  Nat Immunol       Date:  2001-06       Impact factor: 25.606

5.  Cutting edge: molecular analysis of the negative regulatory function of lymphocyte activation gene-3.

Authors:  Creg J Workman; Kari J Dugger; Dario A A Vignali
Journal:  J Immunol       Date:  2002-11-15       Impact factor: 5.422

6.  Maturation and activation of dendritic cells induced by lymphocyte activation gene-3 (CD223).

Authors:  Susanne Andreae; Fabienne Piras; Nicolas Burdin; Frédéric Triebel
Journal:  J Immunol       Date:  2002-04-15       Impact factor: 5.422

7.  T lymphocyte costimulation mediated by reorganization of membrane microdomains.

Authors:  A Viola; S Schroeder; Y Sakakibara; A Lanzavecchia
Journal:  Science       Date:  1999-01-29       Impact factor: 47.728

Review 8.  CTLA-4: new insights into its biological function and use in tumor immunotherapy.

Authors:  Jackson G Egen; Michael S Kuhns; James P Allison
Journal:  Nat Immunol       Date:  2002-07       Impact factor: 25.606

9.  Cytotoxic T lymphocyte antigen 4 and CD28 modulate cell surface raft expression in their regulation of T cell function.

Authors:  M Martin; H Schneider; A Azouz; C E Rudd
Journal:  J Exp Med       Date:  2001-12-03       Impact factor: 14.307

10.  Surface cytotoxic T lymphocyte-associated antigen 4 partitions within lipid rafts and relocates to the immunological synapse under conditions of inhibition of T cell activation.

Authors:  Peter J Darlington; Miren L Baroja; Thu A Chau; Eric Siu; Vincent Ling; Beatriz M Carreno; Joaquín Madrenas
Journal:  J Exp Med       Date:  2002-05-20       Impact factor: 14.307

View more
  63 in total

1.  A T2 cytokine environment may not limit T1 responses in human immunodeficiency virus patients with a favourable response to antiretroviral therapy.

Authors:  Patricia Price; Niamh M Keane; Silvia Lee; Andrew F Y Lim; Elizabeth J McKinnon; Martyn A French
Journal:  Immunology       Date:  2006-06-22       Impact factor: 7.397

2.  Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer.

Authors:  Junko Matsuzaki; Sacha Gnjatic; Paulette Mhawech-Fauceglia; Amy Beck; Austin Miller; Takemasa Tsuji; Cheryl Eppolito; Feng Qian; Shashikant Lele; Protul Shrikant; Lloyd J Old; Kunle Odunsi
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-12       Impact factor: 11.205

3.  CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells.

Authors:  Yongping Zhang; Xingying Zhang; Chen Cheng; Wei Mu; Xiaojuan Liu; Na Li; Xiaofei Wei; Xiang Liu; Changqing Xia; Haoyi Wang
Journal:  Front Med       Date:  2017-06-17       Impact factor: 4.592

Review 4.  Tumor microenvironmental influences on dendritic cell and T cell function: A focus on clinically relevant immunologic and metabolic checkpoints.

Authors:  Kristian M Hargadon
Journal:  Clin Transl Med       Date:  2020-01

5.  Antibody-mediated depletion of lymphocyte-activation gene-3 (LAG-3(+) )-activated T lymphocytes prevents delayed-type hypersensitivity in non-human primates.

Authors:  N Poirier; T Haudebourg; C Brignone; N Dilek; J Hervouet; D Minault; F Coulon; R V de Silly; F Triebel; G Blancho; B Vanhove
Journal:  Clin Exp Immunol       Date:  2011-02-24       Impact factor: 4.330

Review 6.  Exploring the NK cell platform for cancer immunotherapy.

Authors:  Jacob A Myers; Jeffrey S Miller
Journal:  Nat Rev Clin Oncol       Date:  2020-09-15       Impact factor: 66.675

Review 7.  The Potential Role of Inhibitory Receptors in the Treatment of Psoriasis.

Authors:  Neha Shah; Sabina Sandigursky; Adam Mor
Journal:  Bull Hosp Jt Dis (2013)       Date:  2017-05

Review 8.  Cytokine production and dysregulation in HIV pathogenesis: lessons for development of therapeutics and vaccines.

Authors:  Morgan A Reuter; Carolina Pombo; Michael R Betts
Journal:  Cytokine Growth Factor Rev       Date:  2012-06-27       Impact factor: 7.638

9.  Identification of a human CD8+ regulatory T cell subset that mediates suppression through the chemokine CC chemokine ligand 4.

Authors:  Simone A Joosten; Krista E van Meijgaarden; Nigel D L Savage; Tjitske de Boer; Frédéric Triebel; Annemieke van der Wal; Emile de Heer; Michèl R Klein; Annemieke Geluk; Tom H M Ottenhoff
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-02       Impact factor: 11.205

Review 10.  The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints.

Authors:  Santosha Vardhana; Anas Younes
Journal:  Haematologica       Date:  2016-07       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.